All patients underwent genetic evaluation and they reported different types of mutations that induce anatomic-functional impairment of the rods.~Patients affected by bilateral dry age-related macular degeneration (Geographic type) will be recruited as well.~After selecting the patients to be enrolled, the study will proceed with the vitrectomy surgery and subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) provided by the Umbilical Cord Bank according to the procedures provided for by the current legislation on blood components for non-transfusion use.~A complete ophthalmological examination will be performed at 1, 3, 6, and 12 months. They will include:~Anterior segment biomicroscopy~direct and indirect ophthalmoscopy~ETDRS visual acuity assessment~intraocular pressure measurement~optical coherence tomography (OCT)~OCT Angiography (OCTA)~The following assessments will be performed at baseline and at 6 and 12 months.~Microperimetry~Electroretinogram (ERG)~Visually evoked potential (VEP)~contrast sensitivity (MARS tables)~Goldmann perimetry~Some morpho-functional data will also be collected in the contralateral eye and used as the control group.~To ensure the best safety for the patient, the first 5 eyes will be separated by a minimum of 20 days in order to observe the post-surgical evolution.
The study will provides the enrollment of patients with genetic retinal dystrophies with primary rod impairment and dry age-related macular degeneration (Geographic type) A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.~A complete morpho-functional ophthalmological evaluation will be performed in all patients at each control.